The product profile of Zuragen™ (formerly known as AAT-023) holds tremendous potential to address a significant unmet medical need in both the chronic and acute care patient populations. Zuragen™ is an innovative, non-antibiotic, injectable therapy designed to prevent and significantly reduce the incidence of catheter-related bloodstream infections (CRBSI) and maintain catheter patency. In-vitro studies have demonstrated rapid and significant efficacy against a broad spectrum of bacteria and complete elimination of biofilm.
The pivotal clinical trial, also known as the AZEPTIC Trial, is a multi-centered study evaluating the efficacy and safety of Zuragen™. The trial consists of 415 hemodialysis patients at 25 study sites across the United States. Patient enrollment in the AZEPTIC Trial was completed in December, 2007. We would like to acknowledge that this pivitol trial is partially funded by a Phase I & II SBIR Grant from the National Institutes of Health (NIH) as well as the support of the Indiana 21st Century Research and Technology Fund.
Official clinical trial team members can gain access to the private clinical trial site by contacting a member of the Ash Access Team for login/password information.